{"schema_version":"secwatch.filing_event.v1","accession":"0001654954-25-002886","form_type":"8-K","ticker":"DRMA","cik":"0001853816","company_name":"Dermata Therapeutics, Inc.","filed_at":"2025-03-17T23:59:59+00:00","discovered_at":"2026-05-14T18:03:05.315975+00:00","generated_at":"2026-05-24T16:37:34.783925+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Dermata reports FY2024 cash burn; Phase 3 STAR-1 topline expected by end of March 2025","bullets":["Cash and cash equivalents $3.2M as of Dec. 31, 2024, down from $7.4M; expects funding into Q3 2025 after $2.55M Jan. 2025 PIPE.","R&D expense $8.2M in 2024 vs $4.1M in 2023, driven by $4.9M increase in Phase 3 STAR-1 clinical trial costs.","Topline results from XYNGARI Phase 3 STAR-1 acne trial expected by end of March 2025.","Entered Clinical Trial Collaboration Agreement with Revance (Crown Laboratories) to study DMT410 with DAXXIFY for hyperhidrosis.","G&A expense $4.3M in 2024 vs $4.0M in 2023, primarily due to increased audit fees from auditor change."],"urls":{"canonical":"https://secwatch.observer/filing/0001654954-25-002886","json":"https://secwatch.observer/filing/0001654954-25-002886.json","markdown":"https://secwatch.observer/filing/0001654954-25-002886.md","text":"https://secwatch.observer/filing/0001654954-25-002886.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1853816/000165495425002886/0001654954-25-002886-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1853816/000165495425002886/drma_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T16:37:34.783925+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}